Published in RMD Open on September 14, 2017
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Evolving concepts of rheumatoid arthritis. Nature (2003) 14.31
Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res (2010) 9.95
Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum (2000) 2.71
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol (2012) 2.28
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol (2006) 1.91
Arthritis induces early bone high turnover, structural degradation and mechanical weakness. PLoS One (2015) 1.42
Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis (2012) 1.32
Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther (2010) 1.25
Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem (2011) 1.18
Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther (2009) 1.12
Biochemical and mechanical properties of subchondral bone in osteoarthritis. Biorheology (2004) 1.11
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res (2005) 1.11
Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Invest (2009) 1.07
Review: Collagen markers in early arthritic diseases. Clin Chim Acta (2005) 1.06
The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol (2003) 1.06
Methotrexate inhibits NF-κB activity via long intergenic (noncoding) RNA-p21 induction. Arthritis Rheumatol (2014) 1.05
Osteoporosis and arthritis. Ann Rheum Dis (1990) 1.04
From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis (2010) 1.02
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther (2009) 1.02
The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res (2000) 1.02
The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage (2006) 1.02
Celastrus and its bioactive celastrol protect against bone damage in autoimmune arthritis by modulating osteoimmune cross-talk. J Biol Chem (2012) 1.01
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J Clin Immunol (2008) 0.99
Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum (1992) 0.98
Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun Rev (2012) 0.97
Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-κB-mediated matrix metalloproteinase-9 expression. PLoS One (2013) 0.93
Infrared spectroscopy indicates altered bone turnover and remodeling activity in renal osteodystrophy. J Bone Miner Res (2010) 0.93
Small molecule inhibitors of IkappaB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J (2010) 0.91
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines. Bioorg Med Chem (2012) 0.90
Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Int Immunopharmacol (2012) 0.89
Rheumatoid arthritis bone fragility is associated with upregulation of IL17 and DKK1 gene expression. Clin Rev Allergy Immunol (2014) 0.89
The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol (1994) 0.89
Phenotypic characterization of osteoarthritic osteocytes from the sclerotic zones: a possible pathological role in subchondral bone sclerosis. Int J Biol Sci (2012) 0.87
Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. Arthritis Res Ther (2015) 0.87
Reinnervation of post-arthritic joints in the rat. Clin Exp Rheumatol (1996) 0.86
Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid Arthritis. Arthritis Rheumatol (2015) 0.86
Celastrol, an inhibitor of heat shock protein 90β potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes. Eur J Pharmacol (2013) 0.84
Caspase-1 is active since the early phase of rheumatoid arthritis. Clin Exp Rheumatol (2012) 0.82
Reduced tissue hardness of trabecular bone is associated with severe osteoarthritis. J Biomech (2011) 0.81
Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats. PLoS One (2015) 0.80
Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors. J Bone Miner Metab (2015) 0.80
Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ. Clin Immunol (2015) 0.80
New insights to the role of aryl hydrocarbon receptor in bone phenotype and in dioxin-induced modulation of bone microarchitecture and material properties. Toxicol Appl Pharmacol (2013) 0.78
Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. Br J Pharmacol (1999) 0.78
Multi-level femoral morphology and mechanical properties of rats of different ages. Bone (2015) 0.77
Celastrol inhibits inflammatory stimuli-induced neutrophil extracellular trap formation. Curr Mol Med (2015) 0.77
Celastrol attenuates bone erosion in collagen-Induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7. Int Immunopharmacol (2014) 0.77
Early elevation in circulating levels of C-telopeptides of type II collagen predicts structural damage in articular cartilage in the rodent model of collagen-induced arthritis. Arthritis Rheum (2006) 0.77
Celastrol, an NF-κB inhibitor, ameliorates hypercalciuria and articular cartilage lesions in a mouse model of secondary osteoporosis. J Pharmacol Sci (2016) 0.76
Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner. J Ethnopharmacol (2015) 0.76
Short time administration of antirheumatic drugs - methotrexate as a strong inhibitor of osteoblast's proliferation in vitro. Head Face Med (2012) 0.75
Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis. BMC Complement Altern Med (2016) 0.75
Near Infrared Spectroscopy Enables Differentiation of Mechanically and Enzymatically Induced Cartilage Injuries. Ann Biomed Eng (2020) 0.75
Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases. Front Med (Lausanne) (2017) 0.75
Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model. Rheumatology (Oxford) (2017) 0.75